C. Whitesitt

发表

SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIPS OF BENZOPHENONES AS INHIBITORS OF CATHEPSIN D

D. R. Berry, S. Little, C. Whitesitt, 1996 .

Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects

F. Bymaster, A. Fink-Jensen, C. Mitch, 1998, Brain Research.

1,2,5-Thiadiazole analogues of aceclidine as potent m1 muscarinic agonists.

L Jeppesen, J S Ward, F. Bymaster, 1998, Journal of medicinal chemistry.

Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease

F. Bymaster, L. Farde, P. Suzdak, 1997 .

Leukotriene (LT) receptor antagonists. Heterocycle-linked tetrazoles and carboxylic acids. LY203647

C. Whitesitt, S. Sigmund, W. S. Marshall, 1989, Agents and Actions.

Effects of the M1 agonist xanomeline on processing of human beta-amyloid precursor protein (FAD, Swedish mutant) transfected into Chinese hamster ovary-m1 cells.

F. Bymaster, A. Fink-Jensen, C. Mitch, 1998, Biochemical and biophysical research communications.

Structural evolution and pharmacology of a novel series of triacid angiotensin II receptor antagonists.

C. Whitesitt, R. Simon, J. Reel, 1994, Journal of medicinal chemistry.

Pharmacologic analysis of LY188695 (KB-2413), 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)-benzimidazole difumarate, a potent histamine1 receptor antagonist

C. Whitesitt, J. Fleisch, L. Rinkema, 1987, Agents and Actions.

Chiral recognition of the angiotensin II (AT1) receptor by a highly potent phenoxyproline octanoamide

C. J. Barnett, D. B. Boyd, J. Deeter, 1994 .

Effect of lipophilic substituents on some biological properties of indoles.

C. Whitesitt, C. W. Whitehead, 1974, Journal of medicinal chemistry.

Reactions of 4-chloroazetidinones with tributyl tin hydride

D. K. Herron, C. Whitesitt, 1978 .

Potential role of muscarinic receptors in schizophrenia.

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 1999, Life sciences.

In vivo pharmacology of butylthio[2.2.2] (LY297802 / NNC11-1053), an orally acting antinociceptive muscarinic agonist.

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 1997, Life sciences.

Identification of side chains on 1,2,5-thiadiazole-azacycles optimal for muscarinic m1 receptor activation.

F. Bymaster, A. Fink-Jensen, J. Ward, 1998, Bioorganic & Medicinal Chemistry Letters.

Evaluation of LY203647 on cardiovascular leukotriene D4 receptors and myocardial reperfusion injury.

C. Whitesitt, W. S. Marshall, B. R. Macdonald, 1992, The Journal of pharmacology and experimental therapeutics.

Direct pharmacological comparison of the muscarinic receptors mediating relaxation and contraction in the rabbit thoracic aorta.

F. Bymaster, C. Mitch, J. Ward, 1999, General pharmacology.

Muscarinic receptor agonists decrease cocaine self-administration rates in drug-naive mice.

F. Bymaster, A. Fink-Jensen, Michael D B Swedberg, 2000, European journal of pharmacology.

Induction of peroxisomal β-oxidation in the rat liver in vivo and in vitro by tetrazole-substituted acetophenones: Structure-activity relationships

D. K. Herron, P. Eacho, C. Whitesitt, 1989 .

Muscarinic agonists exhibit functional dopamine antagonism in unilaterally 6-OHDA lesioned rats.

F. Bymaster, A. Fink-Jensen, P. Kristensen, 1998, Neuroreport.

Discovery, purification, and properties of o-phthalyl amidase from Xanthobacter agilis

M. Zmijewski, A. Kreuzman, W. Yeh, 1996 .